{
    "id": 642,
    "fullName": "KRAS G12D",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "KRAS G12D is a hotspot mutation that lies within a GTP-binding region of the Kras protein (UniProt.org). G12D results in decreased Kras GTPase activity and increased activation of downstream signaling, promotes tumor formation in mouse models (PMID: 16474405, PMID: 26037647, PMID: 22871572), and is transforming in cell culture (PMID: 29533785).",
            "references": [
                {
                    "id": 3052,
                    "pubMedId": 26037647,
                    "title": "Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26037647"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 840,
                    "pubMedId": 16474405,
                    "title": "Germline KRAS mutations cause Noonan syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16474405"
                },
                {
                    "id": 3442,
                    "pubMedId": 22871572,
                    "title": "KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22871572"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3845,
        "geneSymbol": "KRAS",
        "terms": [
            "KRAS",
            "'C-K-RAS",
            "C-K-RAS",
            "c-Ki-ras",
            "c-Ki-ras2",
            "CFC2",
            "K-Ras",
            "K-Ras 2",
            "K-RAS2A",
            "K-RAS2B",
            "K-RAS4A",
            "K-RAS4B",
            "KI-RAS",
            "KRAS1",
            "KRAS2",
            "NS",
            "NS3",
            "OES",
            "RALD",
            "RASK2"
        ]
    },
    "variant": "G12D",
    "createDate": "06/05/2014",
    "updateDate": "10/22/2019",
    "referenceTranscriptCoordinates": {
        "id": 157055,
        "transcript": "NM_033360",
        "gDna": "chr12:g.25245350C>T",
        "cDna": "c.35G>A",
        "protein": "p.G12D",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2771,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-733 induce tumor regression in patient derived xenografts of cholangiocarcinoma with Kras G12D mutations (AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2523).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 932,
                "therapyName": "TAK-733",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3467,
                    "pubMedId": null,
                    "title": "BRAF is not the only predictor of sensitivity in vitro and in vivo for TAK-733, a selective potent inhibitor of MEK1/2",
                    "url": "http://cancerres.aacrjournals.org/content/70/8_Supplement/2523.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16044,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GS-493 and Mekinist (trametinib) synergistically inhibited growth of pancreatic ductal adenocarcinoma cells harboring KRAS G12D in culture (PMID: 29808009).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 7865,
                "therapyName": "GS-493 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14154,
                    "pubMedId": 29808009,
                    "title": "Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29808009"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16046,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SHP099 and Mekinist (trametinib) synergistically inhibited growth of pancreatic ductal adenocarcinoma cells harboring KRAS G12D in culture, and inhibited tumor growth in patient-derived xenograft (PDX) models (PMID: 29808009).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 7401,
                "therapyName": "SHP099 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14154,
                    "pubMedId": 29808009,
                    "title": "Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29808009"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19004,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 did not inhibit Erk1/2 phosphorylation and viability of pancreatic cancer cells harboring KRAS G12D in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18642,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Afinitor (everolimus) and Linsitinib (OSI-906) inhibited PI3K/AKT and mTOR signaling, resulted in synergistic growth inhibition in non-small cell lung cancer (NSCLC) cell lines harboring KRAS G12D in culture, and induced short-term tumor regression in a KRAS G12D-driven mouse model of NSCLC (PMID: 31534020).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 8785,
                "therapyName": "Everolimus + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2764,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) demonstrated limited efficacy as a single agent in a pancreatic cell line xenograft model harboring KRAS G12D (PMID: 22952903).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3462,
                    "pubMedId": 22952903,
                    "title": "K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22952903"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1290,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 did not induce tumor shrinkage in mouse lung cancer models carrying KRAS G12D (PMID: 19029981).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 216,
                    "pubMedId": 19029981,
                    "title": "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029981"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2463,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, UC-773587 did not inhibit growth of pancreatic cancer cells harboring KRAS G12D in culture (PMID: 25825487).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 2860,
                "therapyName": "UC-773587",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3114,
                    "pubMedId": 25825487,
                    "title": "Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25825487"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16187,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Taxol (paclitaxel) and Mektovi (binimetinib) combination therapy demonstrated clinical benefit in three patients with platinum resistant/refractory epithelial ovarian cancer harboring activating mutations in KRAS, with one partial response and one stable disease in patients with KRAS G12D and stable disease in a patient with KRAS G12V (PMID: 29844129; NCT01649336).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 2010,
                "therapyName": "Binimetinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2152,
                "name": "ovary epithelial cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14290,
                    "pubMedId": 29844129,
                    "title": "Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29844129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 803,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring the KRAS G12D mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 26,
                    "pubMedId": 23455880,
                    "title": "KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23455880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2763,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Pictilisib (GDC-0941) and Selumetinib (AZD6244) worked synergistically to induce tumor regression in a pancreatic cancer cell line xenograft model harboring KRAS G12D (PMID: 22952903).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 3024,
                "therapyName": "Pictilisib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3462,
                    "pubMedId": 22952903,
                    "title": "K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22952903"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16021,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit growth of colon cancer cells harboring KRAS G12D in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11327,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of pancreatic cancer cells harboring KRAS G12D (PMID: 28615361).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 5914,
                "therapyName": "AZD4785",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9180,
                    "pubMedId": 28615361,
                    "title": "Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615361"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8562,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rigosertib (ON 01910.Na) inhibited tumorigenesis in transgenic animal model of pancreatic cancer driven by KRAS G12D (PMID: 27104980).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 1046,
                "therapyName": "Rigosertib Sodium",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6686,
                    "pubMedId": 27104980,
                    "title": "A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27104980"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19110,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R11.1.6 and ZSTK474 combination therapy did not inhibit cell proliferation in a pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 29720559).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 8912,
                "therapyName": "R11.1.6 + ZSTK474",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16741,
                    "pubMedId": 29720559,
                    "title": "A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29720559"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20586,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, CV301 treatment was well-tolerated, and a microsatellite stable (MSS) colorectal cancer patient harboring KRAS G12D achieved a partial response at 78 weeks with a 30.6% reduction in liver lesion (PMID: 31110074; NCT02840994).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 5243,
                "therapyName": "CV301",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17945,
                    "pubMedId": 31110074,
                    "title": "A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31110074"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 980,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the treatment of KRAS G12D mutant mouse lung cancer with PX-866, a PI3K inhibitor, resulted in inhibition of tumor growth (PMID: 18493606).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 881,
                "therapyName": "PX-866",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 641,
                    "pubMedId": 18493606,
                    "title": "Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18493606"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16041,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GS-493 and Selumetinib (AZD6244) synergistically inhibited growth of pancreatic ductal adenocarcinoma cells harboring KRAS G12D in culture (PMID: 29808009).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 7864,
                "therapyName": "GS-493 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14154,
                    "pubMedId": 29808009,
                    "title": "Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29808009"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1291,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 in combination with Selumetinib (AZD6244) induced tumor shrinkage in mouse lung cancer models carrying KRAS G12D (PMID: 19029981).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 216,
                    "pubMedId": 19029981,
                    "title": "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029981"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19093,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R11.1.6 did not inhibit cell proliferation and colony formation in a colorectal cancer cell line harboring KRAS G12D in culture (PMID: 29720559).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 8686,
                "therapyName": "R11.1.6",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16741,
                    "pubMedId": 29720559,
                    "title": "A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29720559"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 978,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the treatment of a mouse model lung adenocarcinoma harboring the KRAS G12D mutant with selumetinib, a MEK inhibitor, resulted in modest tumor regression (PMID: 19029981).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 216,
                    "pubMedId": 19029981,
                    "title": "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029981"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9211,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Luminespib (AUY922) inhibited growth of a colon cancer cell line harboring KRAS G12D in culture (PMID: 26832792).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 647,
                "therapyName": "Luminespib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5083,
                    "pubMedId": 26832792,
                    "title": "Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832792"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15057,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, pancreatic ductal adenocarcinoma cells harboring KRAS G12D demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture when compared to the combined therapy of Selumetinib (AZD6244) and SHP099 (PMID: 30045908).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 12547,
                    "pubMedId": 30045908,
                    "title": "SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045908"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 979,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mouse lung adenocarcinoma model harboring the KRAS G12D mutation treated with a combination of the MEK inhibitor selumetinib (AZD6244) and the PI3K inhibitor BEZ235 resulted in significant tumor regression (PMID: 19029981).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 216,
                    "pubMedId": 19029981,
                    "title": "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029981"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14057,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RAF709 and Mekinist (trametinib) synergistically inhibited Erk signaling and growth of pancreatic adenocarcinoma cells in culture, resulted in tumor regression in cell line xenograft models (PMID: 29343524).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 6997,
                "therapyName": "RAF709 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11434,
                    "pubMedId": 29343524,
                    "title": "Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29343524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2464,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, UC-857993 did not inhibit growth of pancreatic cancer cells harboring KRAS G12D in culture (PMID: 25825487).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 2861,
                "therapyName": "UC-857993",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3114,
                    "pubMedId": 25825487,
                    "title": "Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25825487"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19103,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R11.1.6 and Wortmannin combination therapy did not inhibit cell proliferation in a pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 29720559).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 8911,
                "therapyName": "R11.1.6 + Wortmannin",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16741,
                    "pubMedId": 29720559,
                    "title": "A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29720559"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9099,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Aphanin inhibited proliferation and induced apoptosis in pancreatic cancer cells harboring KRAS G12D in culture (PMID: 27333990).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 4900,
                "therapyName": "Aphanin",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6915,
                    "pubMedId": 27333990,
                    "title": "Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27333990"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2711,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8055 worked synergistically with Adavosertib (MK-1775) to inhibit proliferation and promote apoptosis in transformed cells expressing KRAS G12D in culture (PMID: 24791855).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 3017,
                "therapyName": "Adavosertib + AZD8055",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 422,
                    "pubMedId": 24791855,
                    "title": "Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24791855"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16020,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit growth of pancreatic cancer cells harboring KRAS G12D in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2730,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY294002 reduced phosphorylation of Akt in pancreatic epithelial cells expressing Kras G12D (PMID: 22871572).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 1062,
                "therapyName": "LY294002",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3442,
                    "pubMedId": 22871572,
                    "title": "KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22871572"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19957,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGTI-2734 inhibited tumor growth in pancreatic ductal adenocarcinoma patient-derived xenograft (PDX) models harboring KRAS G12D, and inhibited viability of primary patient cells harboring KRAS G12D in culture (PMID: 31227505).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 9260,
                "therapyName": "FGTI-2734",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17639,
                    "pubMedId": 31227505,
                    "title": "Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227505"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4618,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SH-1242 inhibited lung tumor growth in a KRAS G12D-expressing transgenic mouse model that forms spontaneous lung tumors (PMID: 26645561).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 3552,
                "therapyName": "SH-1242",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4627,
                    "pubMedId": 26645561,
                    "title": "Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645561"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19101,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R11.1.6 and Wortmannin combination therapy did not inhibit cell proliferation in a colorectal cancer cell line harboring KRAS G12D in culture (PMID: 29720559).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 8911,
                "therapyName": "R11.1.6 + Wortmannin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16741,
                    "pubMedId": 29720559,
                    "title": "A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29720559"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2759,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) demonstrated efficacy in a mouse model of chronic myelomonocytic leukemia expressing KRAS G12D (ASH Annual Meeting Abstracts 2012 120: 2862).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 4972,
                "name": "myelodysplastic/myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3460,
                    "pubMedId": null,
                    "title": "The PI3K Inhibitor GDC-0941 Attenuates Disease in a KrasG12D Mouse Model of CMML and JMML.",
                    "url": "http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/2862?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=GDC-0941&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16022,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 inhibited growth of colorectal cancer cells harboring KRAS G12D in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17585,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines harboring KRAS G12D demonstrated growth rates similar to cells expressing wild-type KRAS when treated with SHP099 in culture (PMID: 30952657).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15680,
                    "pubMedId": 30952657,
                    "title": "Tissue-Specific Oncogenic Activity of KRASA146T.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30952657"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13552,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AR-mTOR-26 treatment resulted in antitumor activity in lung cancer cell line xenograft models harboring KRAS G12D (Cancer Res 2010;70(8 Suppl):Abstract nr 4484).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 3850,
                "therapyName": "AR-mTOR-26",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5033,
                    "pubMedId": null,
                    "title": "Abstract 4484: AR-mTOR-26 - A potent, selective mTORC 1/2 kinase inhibitor for the treatment of malignancy",
                    "url": "http://cancerres.aacrjournals.org/content/70/8_Supplement/4484.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19094,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R11.1.6 treatment did not inhibit cell proliferation and colony formation in a pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 29720559).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 8686,
                "therapyName": "R11.1.6",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16741,
                    "pubMedId": 29720559,
                    "title": "A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29720559"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7129,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment resulted in continued tumor growth in xenograft models of patient derived colorectal cancer cells harboring KRAS G12D (PMID: 26243863).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 4359,
                "therapyName": "Neratinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16019,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit growth of lung cancer cells harboring KRAS G12D in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2721,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Aliqopa (copanlisib) and Refametinib (BAY86-9766) worked synergistically to inhibit proliferation and increase apoptosis of biliary tract cancer cells harboring KRAS G12D in culture (Cancer Res April 15, 2012 72:869).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 3018,
                "therapyName": "Copanlisib + Refametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4607,
                "name": "biliary tract cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3436,
                    "pubMedId": null,
                    "title": "Abstract 869: Potent in vitro and in vivo anti-tumor activity of PI3K inhibitor BAY 80-6946 and MEK inhibitor BAY 86-9766 in preclinical biliary tract cancer models",
                    "url": "http://cancerres.aacrjournals.org/content/72/8_Supplement/869.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19106,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R11.1.6 and ZSTK474 combination therapy did not inhibit cell proliferation in a colorectal cancer cell line harboring KRAS G12D in culture (PMID: 29720559).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 8912,
                "therapyName": "R11.1.6 + ZSTK474",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16741,
                    "pubMedId": 29720559,
                    "title": "A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29720559"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2747,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, treatment with Reolysin (pelareorep) in combination with Gemzar (gemcitabine) resulted in stable disease in a patient with pancreatic cancer harboring KRAS G12D (PMID: 26156229).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 3020,
                "therapyName": "Gemcitabine + Reolysin",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3451,
                    "pubMedId": 26156229,
                    "title": "The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26156229"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12279,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of PD-0325901 and ZSTK474 inhibited tumor growth of colorectal cancer cell line xenograft models harboring KRAS G12D (PMID: 28775144).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 6419,
                "therapyName": "PD-0325901 + ZSTK474",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10258,
                    "pubMedId": 28775144,
                    "title": "A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28775144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12196,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 and Erbitux (cetuximab) worked synergistically, resulting in tumor regression in patient-derived xenograft models of colorectal cancer harboring KRAS G12D (PMID: 28611205).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 6338,
                "therapyName": "Cetuximab + LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15044,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Selumetinib (AZD6244) and SHP099 resulted in a synergistic effect, demonstrating reduced cell proliferation and decreased colony formation in pancreatic ductal adenocarcinoma cells harboring KRAS G12D (PMID: 30045908).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 7400,
                "therapyName": "Selumetinib + SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12547,
                    "pubMedId": 30045908,
                    "title": "SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045908"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2739,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) and Tyrphostin B42 (AG-490) worked synergistically to inhibit proliferation and induce apoptosis in gastric cancer cell lines harboring KRAS G12D in culture (PMID: 22159814).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 3019,
                "therapyName": "Buparlisib + Tyrphostin B42",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3447,
                    "pubMedId": 22159814,
                    "title": "NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22159814"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12277,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ST-162 treatment inhibited tumor growth of colorectal cancer cell line xenograft models harboring KRAS G12D (PMID: 28775144).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 6418,
                "therapyName": "ST-162",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10258,
                    "pubMedId": 28775144,
                    "title": "A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28775144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7377,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and Iclusig (ponatinib) induced cell death in tumors and prolonged survival in an animal model of pancreatic cancer harboring KRAS G12D (PMID: 27338794).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 4477,
                "therapyName": "Ponatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18652,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, addition of low dose Mekinist (trametinib) to Afinitor (everolimus) and Linsitinib (OSI-906) combination treatment enhanced growth inhibition by 75% or more in non-small cell lung cancer (NSCLC) cell lines harboring KRAS G12D in culture, and resulted in prolonged tumor regression in a KRAS G12D-driven mouse model of NSCLC (PMID: 31534020).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 8786,
                "therapyName": "Everolimus + Linsitinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2733,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-0325901 inhibited growth of lung adenocarcinomas in mouse models expressing Kras G12D (PMID: 22684718).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3443,
                    "pubMedId": 22684718,
                    "title": "Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22684718"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18656,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, addition of low dose Mekinist (trametinib) to AZD8055 and Linsitinib (OSI-906) combination treatment enhanced growth inhibition by 75% or more in non-small cell lung cancer cell lines harboring KRAS G12D in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 8788,
                "therapyName": "AZD8055 + Linsitinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7128,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) treatment resulted in continued tumor growth in xenograft models of patient derived colorectal cancer cells harboring KRAS G12D (PMID: 26243863).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6069,
                    "pubMedId": 26243863,
                    "title": "HER2 activating mutations are targets for colorectal cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26243863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18524,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with the combination of Gedatolisib (PF-05212384) and PD-0325901 resulted in an overall response rate of 11.1% (4/44) and clinical benefit rate of 16.3% (7/44) in patients with a variety of solid tumors, with three ovarian cancer patients harboring KRAS mutations (G12A, G12V, G13D, respectively) and one endometrial cancer patient harboring KRAS G12D achieved partial responses (PMID: 29067643; NCT01347866).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 3025,
                "therapyName": "Gedatolisib + PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10357,
                    "pubMedId": 29067643,
                    "title": "A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29067643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18648,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of AZD8055 and Linsitinib (OSI-906) inhibited PI3K/AKT and mTOR signaling, resulted in synergistic growth inhibition in non-small cell lung cancer cell lines harboring KRAS G12D in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 8787,
                "therapyName": "AZD8055 + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12193,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 resulted in tumor regression in a patient-derived xenograft model of colorectal cancer harboring KRAS G12D, but relapse upon discontinuation of treatment (PMID: 28611205).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 6337,
                "therapyName": "LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9636,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic colorectal cancer harboring KRAS G12D demonstrated regression of metastatic lung lesions and a partial response for 9 months following infusion of autologous tumor-infiltrating lymphocytes containing cytotoxic T-cells that specifically recognize KRAS G12D (PMID: 27959684).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 5112,
                "therapyName": "KRAS mutant-specific TIL",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7358,
                    "pubMedId": 27959684,
                    "title": "T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27959684"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2143,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells harboring PIK3CA G1049R, KRAS G12D, and amplification of PIK3CA in culture (PMID: 22662154).",
            "molecularProfile": {
                "id": 5398,
                "profileName": "KRAS G12D PIK3CA G1049R PIK3CA amp"
            },
            "therapy": {
                "id": 2619,
                "therapyName": "BEZ235 + PD98059",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 348,
                    "pubMedId": 22662154,
                    "title": "Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22662154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2147,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, a patient with pancreatic adenocarcinoma harboring PTEN loss and KRAS G12D was treated with MK-2206 and demonstrated a 23% reduction in tumor size (PMID: 22025163).",
            "molecularProfile": {
                "id": 5589,
                "profileName": "KRAS G12D PTEN loss"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 175,
                    "pubMedId": 22025163,
                    "title": "First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22025163"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2860,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD5363 inhibited proliferation of the AGS gastric cancer cell line, which has been reported to harbor KRAS G12D and PIK3CA E453K mutations (PMID: 24088382, PMID: 19755509).",
            "molecularProfile": {
                "id": 10717,
                "profileName": "KRAS G12D PIK3CA E453K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1081,
                    "pubMedId": 24088382,
                    "title": "The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24088382"
                },
                {
                    "id": 3510,
                    "pubMedId": 19755509,
                    "title": "Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19755509"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2954,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH5132799 inhibited proliferation of endometrial cancer cells harboring PIK3CA G1049R and KRAS G12D mutations in culture (PMID: 21558396).",
            "molecularProfile": {
                "id": 10740,
                "profileName": "KRAS G12D PIK3CA G1049R"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1985,
                    "pubMedId": 21558396,
                    "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21558396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4081,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with a MET amplified adenocarcinoma of the distal esophagus responded to AMG 337 treatment for 2 years, but developed resistance upon emergence of KRAS G12D (PMID: 26432108).",
            "molecularProfile": {
                "id": 17216,
                "profileName": "KRAS G12D MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 4914,
                "name": "esophagus adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4397,
                    "pubMedId": 26432108,
                    "title": "Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4082,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human gastric cancer cell line with high levels of MET expression and expressing KRAS G12D was resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26432108).",
            "molecularProfile": {
                "id": 17217,
                "profileName": "KRAS G12D MET over exp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4397,
                    "pubMedId": 26432108,
                    "title": "Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4442,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mycro3 inhibited tumor growth in transgenic mouse models of Kras G12D-expressing pancreatic adenocarcinoma with Myc overexpression (PMID: 25306215).",
            "molecularProfile": {
                "id": 18158,
                "profileName": "KRAS G12D MYC over exp"
            },
            "therapy": {
                "id": 3507,
                "therapyName": "Mycro3",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4548,
                    "pubMedId": 25306215,
                    "title": "Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25306215"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9550,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SRA737 (CCT245737) resulted in some decreased tumor volume in a pancreatic ductal adenocarcinoma transgenic mouse model harboring KRAS G12D and TP53 R175H when compared to control (PMID: 27167172).",
            "molecularProfile": {
                "id": 18195,
                "profileName": "KRAS G12D TP53 R175H"
            },
            "therapy": {
                "id": 5069,
                "therapyName": "SRA737",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7267,
                    "pubMedId": 27167172,
                    "title": "Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27167172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4467,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of pimasertib and Gemzar (gemcitabine) inhibited tumor growth in a syngeneic mouse model of pancreatic cancer expressing KRAS G12D and TP53 R175H (PMID: 26228206).",
            "molecularProfile": {
                "id": 18195,
                "profileName": "KRAS G12D TP53 R175H"
            },
            "therapy": {
                "id": 3526,
                "therapyName": "Gemcitabine + Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4571,
                    "pubMedId": 26228206,
                    "title": "The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26228206"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8856,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) treatment in transgenic animal models of pancreatic ductal adenocarcinoma harboring KRAS G12D and TP53 R175H resulted in proliferation of tumor cells in interior, hypovascularized tumor regions, but inhibited proliferation in outer, vascularized tumor regions, despite inhibition of mTORC signaling in both regions (PMID: 26144316).",
            "molecularProfile": {
                "id": 18195,
                "profileName": "KRAS G12D TP53 R175H"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6770,
                    "pubMedId": 26144316,
                    "title": "The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26144316"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9549,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gemzar (gemcitabine) resulted in enhanced antitumor efficacy, including decreased tumor volume, when combined with SRA737 (CCT245737) in a pancreatic ductal adenocarcinoma transgenic mouse model harboring KRAS G12D and TP53 R175H (PMID: 27167172).",
            "molecularProfile": {
                "id": 18195,
                "profileName": "KRAS G12D TP53 R175H"
            },
            "therapy": {
                "id": 5070,
                "therapyName": "Gemcitabine + SRA737",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7267,
                    "pubMedId": 27167172,
                    "title": "Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27167172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4520,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YAP1 knockdown enhanced sensitivity of pancreatic cancer cell lines harboring KRAS G12D to Mekinist (trametinib) in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 18276,
                "profileName": "KRAS G12D YAP1 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5409,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) inhibited lung tumor growth in mouse models with KRAS G12D and inactivation of STK11 (LKB1), and demonstrated limited efficacy in tumors with KRAS G12D and wild-type STK11 (PMID: 26574479).",
            "molecularProfile": {
                "id": 20862,
                "profileName": "KRAS G12D STK11 inact mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5053,
                    "pubMedId": 26574479,
                    "title": "Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26574479"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5461,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic cancer cell line harboring KRAS G12D and decreased Stat3 expression demonstrated increased sensitivity to Selumetinib (AZD6244) induced growth inhibition in culture (PMID: 25961376).",
            "molecularProfile": {
                "id": 20921,
                "profileName": "KRAS G12D STAT3 dec exp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5460,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human pancreatic cancer cell line harboring KRAS G12D and decreased Stat3 expression demonstrated increased sensitivity to Mekinist (trametinib) induced growth inhibition in culture and in xenograft models (PMID: 25961376).",
            "molecularProfile": {
                "id": 20921,
                "profileName": "KRAS G12D STAT3 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5462,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic cancer cell line harboring KRAS G12D and over expressing a constitutively active Stat3 demonstrated decreased sensitivity to Selumetinib (AZD6244) induced growth inhibition in culture (PMID: 25961376).",
            "molecularProfile": {
                "id": 20924,
                "profileName": "KRAS G12D STAT3 act mut"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5470,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and Mekinist (trametinib) synergistically inhibited growth of Stat3-positive pancreatic cancer cells harboring KRAS G12D in culture (PMID: 25961376).",
            "molecularProfile": {
                "id": 20929,
                "profileName": "KRAS G12D STAT3 pos"
            },
            "therapy": {
                "id": 3868,
                "therapyName": "Ruxolitinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5465,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY5 and Mekinist (trametinib) synergistically inhibited growth of Stat3-positive pancreatic cancer cells harboring KRAS G12D in culture (PMID: 25961376).",
            "molecularProfile": {
                "id": 20929,
                "profileName": "KRAS G12D STAT3 pos"
            },
            "therapy": {
                "id": 3863,
                "therapyName": "LY5 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5468,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY5 and Mekinist (trametinib) synergistically inhibited growth of Stat3-positive colorectal cancer cells harboring KRAS G12D in culture (PMID: 25961376).",
            "molecularProfile": {
                "id": 20929,
                "profileName": "KRAS G12D STAT3 pos"
            },
            "therapy": {
                "id": 3863,
                "therapyName": "LY5 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5469,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY5 and Selumetinib (AZD6244) synergistically inhibited growth of Stat3-positive colorectal cancer cells harboring KRAS G12D in culture (PMID: 25961376).",
            "molecularProfile": {
                "id": 20929,
                "profileName": "KRAS G12D STAT3 pos"
            },
            "therapy": {
                "id": 3866,
                "therapyName": "LY5 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5471,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and Selumetinib (AZD6244) synergistically inhibited growth of Stat3-positive pancreatic cancer cells harboring KRAS G12D in culture (PMID: 25961376).",
            "molecularProfile": {
                "id": 20929,
                "profileName": "KRAS G12D STAT3 pos"
            },
            "therapy": {
                "id": 3869,
                "therapyName": "Ruxolitinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5619,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS G12D and PIK3CA Q546L (PMID: 26369631).",
            "molecularProfile": {
                "id": 21301,
                "profileName": "KRAS G12D PIK3CA Q546L"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5128,
                    "pubMedId": 26369631,
                    "title": "Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26369631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6654,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRAS G12D was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).",
            "molecularProfile": {
                "id": 23661,
                "profileName": "EGFR L858R KRAS G12D"
            },
            "therapy": {
                "id": 4190,
                "therapyName": "Afatinib + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5721,
                    "pubMedId": 26341921,
                    "title": "Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Na\u00efve EGFR L858R-Induced Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26341921"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7353,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Sprycel (dasatinib) induced growth inhibition in culture and in xenograft models (PMID: 27231123).",
            "molecularProfile": {
                "id": 25295,
                "profileName": "IDH2 R172K KRAS G12D"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4928,
                "name": "intrahepatic cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6322,
                    "pubMedId": 27231123,
                    "title": "Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27231123"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7354,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition in culture (PMID: 27231123).",
            "molecularProfile": {
                "id": 25295,
                "profileName": "IDH2 R172K KRAS G12D"
            },
            "therapy": {
                "id": 912,
                "therapyName": "Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4928,
                "name": "intrahepatic cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6322,
                    "pubMedId": 27231123,
                    "title": "Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27231123"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7690,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25922,
                "profileName": "BRAF V600E KRAS G12D"
            },
            "therapy": {
                "id": 4541,
                "therapyName": "Cetuximab + Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7691,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25922,
                "profileName": "BRAF V600E KRAS G12D"
            },
            "therapy": {
                "id": 4543,
                "therapyName": "Cetuximab + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7626,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquisition of KRAS G12D (PMID: 27312529).",
            "molecularProfile": {
                "id": 25922,
                "profileName": "BRAF V600E KRAS G12D"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7689,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).",
            "molecularProfile": {
                "id": 25922,
                "profileName": "BRAF V600E KRAS G12D"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6445,
                    "pubMedId": 27312529,
                    "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7887,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type pancreatic cancer cells harboring KRAS G12D in cell line xenograft models (PMID: 19276360).",
            "molecularProfile": {
                "id": 26084,
                "profileName": "BRAF wild-type KRAS G12D"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8506,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture and in xenograft models, resulting in decreased cell survival and tumor growth (PMID: 26676756).",
            "molecularProfile": {
                "id": 26340,
                "profileName": "EZH2 pos KRAS G12D"
            },
            "therapy": {
                "id": 4747,
                "therapyName": "DZNeP + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8505,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).",
            "molecularProfile": {
                "id": 26340,
                "profileName": "EZH2 pos KRAS G12D"
            },
            "therapy": {
                "id": 4748,
                "therapyName": "Selumetinib + Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8516,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",
            "molecularProfile": {
                "id": 26340,
                "profileName": "EZH2 pos KRAS G12D"
            },
            "therapy": {
                "id": 4746,
                "therapyName": "DZNeP + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8504,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of GSK343 did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).",
            "molecularProfile": {
                "id": 26340,
                "profileName": "EZH2 pos KRAS G12D"
            },
            "therapy": {
                "id": 4750,
                "therapyName": "GSK343 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8520,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",
            "molecularProfile": {
                "id": 26340,
                "profileName": "EZH2 pos KRAS G12D"
            },
            "therapy": {
                "id": 4747,
                "therapyName": "DZNeP + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8519,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",
            "molecularProfile": {
                "id": 26340,
                "profileName": "EZH2 pos KRAS G12D"
            },
            "therapy": {
                "id": 4747,
                "therapyName": "DZNeP + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8508,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756).",
            "molecularProfile": {
                "id": 26340,
                "profileName": "EZH2 pos KRAS G12D"
            },
            "therapy": {
                "id": 4749,
                "therapyName": "MK2206 + Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8518,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",
            "molecularProfile": {
                "id": 26340,
                "profileName": "EZH2 pos KRAS G12D"
            },
            "therapy": {
                "id": 4746,
                "therapyName": "DZNeP + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8507,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of GSK343 increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756).",
            "molecularProfile": {
                "id": 26340,
                "profileName": "EZH2 pos KRAS G12D"
            },
            "therapy": {
                "id": 4751,
                "therapyName": "GSK343 + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8500,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).",
            "molecularProfile": {
                "id": 26340,
                "profileName": "EZH2 pos KRAS G12D"
            },
            "therapy": {
                "id": 4746,
                "therapyName": "DZNeP + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8575,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PTEN loss, and TP53 V216M (PMID: 26272063).",
            "molecularProfile": {
                "id": 26364,
                "profileName": "KRAS G12D PTEN loss TP53 V216M"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8576,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, decreased PTEN expression, and TP53 R306* (PMID: 26272063).",
            "molecularProfile": {
                "id": 26365,
                "profileName": "KRAS G12D PTEN dec exp TP53 R306*"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8581,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment resulted in tumor growth stabilization in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D, PIK3CA E545K and H1047L (PMID: 26272063).",
            "molecularProfile": {
                "id": 26369,
                "profileName": "KRAS G12D PIK3CA E545K PIK3CA H1047L TP53 wild-type"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8697,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 stabilized tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",
            "molecularProfile": {
                "id": 26372,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 R248W"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8596,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R and TP53 R248W (PMID: 26272063).",
            "molecularProfile": {
                "id": 26372,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 R248W"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8695,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).",
            "molecularProfile": {
                "id": 26372,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 R248W"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8703,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",
            "molecularProfile": {
                "id": 26376,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8601,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",
            "molecularProfile": {
                "id": 26376,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8702,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",
            "molecularProfile": {
                "id": 26376,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 590,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glucophage (metformin) inhibited cell proliferation and induced apoptosis in a PTEN-expressing human endometrial cancer cell line harboring KRAS G12D in culture and decreased tumor growth in xenograft models (PMID: 24077915).",
            "molecularProfile": {
                "id": 26548,
                "profileName": "KRAS G12D PTEN pos"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 986,
                    "pubMedId": 24077915,
                    "title": "Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24077915"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9190,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26771,
                "profileName": "APC inact mut KRAS G12D"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9200,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) resulted in reduced tumor growth and additive effect on survival compared to single agent in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26771,
                "profileName": "APC inact mut KRAS G12D"
            },
            "therapy": {
                "id": 4932,
                "therapyName": "BEZ235 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9193,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Binimetinib (MEK162) increased apoptosis in tumors and improved survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26771,
                "profileName": "APC inact mut KRAS G12D"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9191,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation, and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26772,
                "profileName": "APC inact mut KRAS G12D PTEN inact mut"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9194,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Binimetinib (MEK162) increased both apoptosis and proliferation in tumors, resulted in no improvement in survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26772,
                "profileName": "APC inact mut KRAS G12D PTEN inact mut"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9201,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) increased survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",
            "molecularProfile": {
                "id": 26772,
                "profileName": "APC inact mut KRAS G12D PTEN inact mut"
            },
            "therapy": {
                "id": 4932,
                "therapyName": "BEZ235 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7007,
                    "pubMedId": 26206338,
                    "title": "Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206338"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9373,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and BEZ235 resulted in stable disease in patient-derived xenograft (PDX) models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, and PTEN R130G, and demonstrated improved efficacy over either agent alone (PMID: 26232337).",
            "molecularProfile": {
                "id": 26839,
                "profileName": "KRAS G12D PIK3CA H1047R PTEN R130G"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7135,
                    "pubMedId": 26232337,
                    "title": "Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26232337"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9375,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BEZ235 slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",
            "molecularProfile": {
                "id": 26839,
                "profileName": "KRAS G12D PIK3CA H1047R PTEN R130G"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7135,
                    "pubMedId": 26232337,
                    "title": "Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26232337"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9374,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Selumetinib (AZD6244) slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",
            "molecularProfile": {
                "id": 26839,
                "profileName": "KRAS G12D PIK3CA H1047R PTEN R130G"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7135,
                    "pubMedId": 26232337,
                    "title": "Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26232337"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9404,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of a murine PD-1 antibody and Rapamune (sirolimus) decreased PD-L1 expression and mTOR activation and resulted in decreased tumor growth compared to either agent alone in a mouse lung adenocarcinoma model expressing KRAS G12D (PMID: 26637667).",
            "molecularProfile": {
                "id": 26840,
                "profileName": "CD274 pos KRAS G12D"
            },
            "therapy": {
                "id": 5014,
                "therapyName": "Sirolimus + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7140,
                    "pubMedId": 26637667,
                    "title": "Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26637667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9834,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JQ1 inhibited tumor growth, decreased tumor cell proliferation, and decreased MYC expression in a mouse model of follicular thryroid carcinoma harboring KRAS G12D and THRB P447fs*16 (PMID: 27440272).",
            "molecularProfile": {
                "id": 27134,
                "profileName": "KRAS G12D THRB P447fs"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 3962,
                "name": "thyroid gland follicular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7659,
                    "pubMedId": 27440272,
                    "title": "Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27440272"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10116,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of IKBKE enhanced the sensitivity of Torin 1 treatment in a pancreatic ductal adenocarcinoma cell line harboring KRAS G12D, demonstrating decreased cell viability and increased apoptotic activity in culture and reduced tumor growth in xenograft models (PMID: 28069799).",
            "molecularProfile": {
                "id": 27260,
                "profileName": "IKBKE dec exp KRAS G12D"
            },
            "therapy": {
                "id": 2247,
                "therapyName": "Torin 1",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8040,
                    "pubMedId": 28069799,
                    "title": "IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28069799"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10885,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12D and TP53 S127Y (PMID: 26855149).",
            "molecularProfile": {
                "id": 27819,
                "profileName": "KRAS G12D TP53 S127Y"
            },
            "therapy": {
                "id": 5671,
                "therapyName": "Dasatinib + Demcizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8887,
                    "pubMedId": 26855149,
                    "title": "Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26855149"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7768,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with colorectal cancer harboring KRAS G12D and PIK3CA Q546R demonstrated sensitivity to treatment with the combination of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for more than 6 months (PMID: 25363205).",
            "molecularProfile": {
                "id": 27864,
                "profileName": "KRAS G12D PIK3CA Q546R"
            },
            "therapy": {
                "id": 4517,
                "therapyName": "Bevacizumab + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6478,
                    "pubMedId": 25363205,
                    "title": "Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25363205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11387,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a KRAS G12D driven lung adenocarcinoma mouse model with homozygous deletion of ATM was sensitive to Lynparza (olaparib), demonstrating reduced tumor volume and greater overall survival when compared to models treated with control (PMID: 28363999).",
            "molecularProfile": {
                "id": 27978,
                "profileName": "ATM del KRAS G12D"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9282,
                    "pubMedId": 28363999,
                    "title": "ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28363999"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11388,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a KRAS G12D driven lung adenocarcinoma mouse model with homozygous deletion of ATM was sensitive to VX-970, demonstrating decreased tumor volume and greater overall survival compared to control treated models (PMID: 28363999).",
            "molecularProfile": {
                "id": 27978,
                "profileName": "ATM del KRAS G12D"
            },
            "therapy": {
                "id": 2879,
                "therapyName": "VX-970",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9282,
                    "pubMedId": 28363999,
                    "title": "ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28363999"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11860,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775) and Platinol (cisplatin) combination treatment resulted in improved survival in transgenic animal models of non-small cell lung carcinoma harboring KRAS G12D and STK11 loss compared to Platinol (cisplatin) alone (PMID: 28652249).",
            "molecularProfile": {
                "id": 28318,
                "profileName": "KRAS G12D STK11 loss"
            },
            "therapy": {
                "id": 1725,
                "therapyName": "Adavosertib + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9874,
                    "pubMedId": 28652249,
                    "title": "WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28652249"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18672,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus), Linsitinib (OSI-906), and Mekinist (trametinib) triple combination treatment resulted in tumor regression in all the tumors in a mouse model harboring KRAS G12D and loss of STK11 (PMID: 31534020).",
            "molecularProfile": {
                "id": 28318,
                "profileName": "KRAS G12D STK11 loss"
            },
            "therapy": {
                "id": 8786,
                "therapyName": "Everolimus + Linsitinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12141,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12D and demonstrating high AKT expression and activity was insensitive to growth inhibition by single agent MEK inhibitors, including PD-0325901, in culture (PMID: 28957417).",
            "molecularProfile": {
                "id": 28492,
                "profileName": "AKT1 over exp AKT2 over exp AKT3 over exp KRAS G12D"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12140,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12D and demonstrating high AKT expression and activity was insensitive to growth inhibition by single agent MEK inhibitors, including Refametinib (BAY86-9766), in culture (PMID: 28957417).",
            "molecularProfile": {
                "id": 28492,
                "profileName": "AKT1 over exp AKT2 over exp AKT3 over exp KRAS G12D"
            },
            "therapy": {
                "id": 888,
                "therapyName": "Refametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12142,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12D and demonstrating high AKT expression and activity was insensitive to growth inhibition by single agent MEK inhibitors, including Mekinist (trametinib), in culture (PMID: 28957417).",
            "molecularProfile": {
                "id": 28492,
                "profileName": "AKT1 over exp AKT2 over exp AKT3 over exp KRAS G12D"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12139,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12D and demonstrating high AKT expression and activity was insensitive to growth inhibition by single agent MEK inhibitors, including Selumetinib (AZD6244), in culture (PMID: 28957417).",
            "molecularProfile": {
                "id": 28492,
                "profileName": "AKT1 over exp AKT2 over exp AKT3 over exp KRAS G12D"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12144,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and Triciribine (API-2) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line harboring KRAS G12D and demonstrating high AKT expression and activity in culture, however, the concentration of Mekinist (trametinib) was above the clinically relevant limit (PMID: 28957417).",
            "molecularProfile": {
                "id": 28492,
                "profileName": "AKT1 over exp AKT2 over exp AKT3 over exp KRAS G12D"
            },
            "therapy": {
                "id": 6312,
                "therapyName": "Trametinib + Triciribine",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15541,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Zelboraf (vemurafenib) to treatment with Mekinist (trametinib) resulted in increased proliferation compared to Mekinist (trametinib) alone in a melanoma cell line harboring BRAF G464E and KRAS G12D in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31087,
                "profileName": "BRAF G464E KRAS G12D"
            },
            "therapy": {
                "id": 4234,
                "therapyName": "Trametinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15523,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF G464E and KRAS G12D in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31087,
                "profileName": "BRAF G464E KRAS G12D"
            },
            "therapy": {
                "id": 7661,
                "therapyName": "Encorafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16040,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CRISPR-Cas9-mediated knock-out of PTPN11 abolished reactivation of MAPK signaling in the presence of Mekinist (trametinib) in pancreatic ductal adenocarcinoma cells harboring KRAS G12D, resulted in enhanced growth inhibition in culture (PMID: 29808009).",
            "molecularProfile": {
                "id": 31380,
                "profileName": "KRAS G12D PTPN11 loss"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14154,
                    "pubMedId": 29808009,
                    "title": "Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29808009"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16039,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CRISPR-Cas9-mediated knock-out of PTPN11 abolished reactivation of MAPK signaling in the presence of Selumetinib (AZD6244) in pancreatic ductal adenocarcinoma cells harboring KRAS G12D, resulted in enhanced growth inhibition in culture (PMID: 29808009).",
            "molecularProfile": {
                "id": 31380,
                "profileName": "KRAS G12D PTPN11 loss"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14154,
                    "pubMedId": 29808009,
                    "title": "Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29808009"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16047,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) in combination with GS-493 inhibited growth of pancreatic ductal adenocarcinoma harboring KRAS G12D and expressing PTPN11 E76A in culture (PMID: 29808009).",
            "molecularProfile": {
                "id": 31390,
                "profileName": "KRAS G12D PTPN11 E76A"
            },
            "therapy": {
                "id": 7864,
                "therapyName": "GS-493 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14154,
                    "pubMedId": 29808009,
                    "title": "Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29808009"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16048,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) in combination with SHP099 did not inhibit growth of pancreatic ductal adenocarcinoma harboring KRAS G12D and expressing PTPN11 E76A in culture (PMID: 29808009).",
            "molecularProfile": {
                "id": 31390,
                "profileName": "KRAS G12D PTPN11 E76A"
            },
            "therapy": {
                "id": 7400,
                "therapyName": "Selumetinib + SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14154,
                    "pubMedId": 29808009,
                    "title": "Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29808009"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17096,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Mekinist (trametinib) and Opdivo (nivolumab) combination treatment resulted in a partial response and rapid decrease of CA-19-9 levels after 8 weeks in a patient with adenocarcinoma of unknown primary with liver and abdominal lymph node metastases harboring KRAS G12D and MLH1 R389W (PMID: 28642281).",
            "molecularProfile": {
                "id": 32333,
                "profileName": "KRAS G12D MLH1 R389W"
            },
            "therapy": {
                "id": 4753,
                "therapyName": "Nivolumab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 305,
                "name": "carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11306,
                    "pubMedId": 28642281,
                    "title": "Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28642281"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19082,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with pancreatic cancer harboring CTRC-NTRK1 and BRAF V600E treated with a combination of Tafinlar (dabrafenib) and Mekinist (trametinib) demonstrated tumor regression, but later showed radiographical progression and was found to have acquired KRAS G12D (PMID: 31406350).",
            "molecularProfile": {
                "id": 33509,
                "profileName": "CTRC - NTRK1 BRAF V600E KRAS G12D"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18708,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with pancreatic cancer harboring CTRC-NTRK1 progressed on Vitrakvi (larotrectinib) treatment, showing acquisition of BRAF V600E via biopsy testing and BRAF V600E and KRAS G12D via cell-free DNA testing (PMID: 31406350).",
            "molecularProfile": {
                "id": 33509,
                "profileName": "CTRC - NTRK1 BRAF V600E KRAS G12D"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19083,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived xenograft (PDX) model with pancreatic cancer harboring CTRC-NTRK1, BRAF V600E, and KRAS G12D demonstrated greater tumor growth inhibition when treated with a combination of Tafinlar (dabrafenib), Mekinist (trametinib), and Vitrakvi (larotrectinib) versus a combination of Tafinlar (dabrafenib) and Mekinst (trametinib) only (PMID: 31406350).",
            "molecularProfile": {
                "id": 33509,
                "profileName": "CTRC - NTRK1 BRAF V600E KRAS G12D"
            },
            "therapy": {
                "id": 8908,
                "therapyName": "Dabrafenib + Larotrectinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18709,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with pancreatic cancer harboring CTRC-NTRK1, BRAF V600E, and KRAS G12D demonstrated resistance to treatment with LOXO-195 (PMID: 31406350).",
            "molecularProfile": {
                "id": 33509,
                "profileName": "CTRC - NTRK1 BRAF V600E KRAS G12D"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18711,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with colorectal cancer harboring LMNA-NTRK1 and NTRK1 G595R demonstrated liver progression while on treatment with LOXO-195 and was found via cell-free DNA (cfDNA) testing to have acquired KRAS G12A, however, upon liver ablation and further LOXO-195 treatment, subsequent cfDNA testing revealed loss of KRAS G12A, but acquisition of KRAS G12D (PMID: 31406350).",
            "molecularProfile": {
                "id": 33513,
                "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12A KRAS G12D"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19121,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of LOXO-195 and Mekinist (trametinib) compared to LOXO-195 treatment alone in colorectal cancer cells harboring LMNA-NTRK1, NTRK1 G595R, and KRAS G12D resulted in decreased cell viability in culture and reduced tumor growth in xenograft models (PMID: 31406350).",
            "molecularProfile": {
                "id": 33515,
                "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12D"
            },
            "therapy": {
                "id": 8914,
                "therapyName": "LOXO-195 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18712,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring LMNA-NTRK1 and NTRK1 G595R underwent prolonged treatment with LOXO-195, developing resistance in culture, and was subsequently found to have acquired KRAS G12D (PMID: 31406350).",
            "molecularProfile": {
                "id": 33515,
                "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12D"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19081,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with colorectal cancer harboring TPM3-NTRK1 developed resistance to treatment with Vitrakvi (larotrectinib), and was found to have acquired NTRK1 G595R, NTRK1 F589L, and KRAS G12D (PMID: 31406350).",
            "molecularProfile": {
                "id": 33930,
                "profileName": "TPM3 - NTRK1 NTRK1 F589L NTRK1 G595R KRAS G12D"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19760,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (METROS), Xalkori (crizotinib) treatment resulted in progressive disease in a patient with pre-treated non-small cell lung cancer harboring MET T1010I and KRAS G12D (PMID: 31416808; NCT02499614).",
            "molecularProfile": {
                "id": 34503,
                "profileName": "KRAS G12D MET T1010I"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17527,
                    "pubMedId": 31416808,
                    "title": "Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31416808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20475,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with pancreatic cancer harboring KRAS G12D and CDKN2A R80* demonstrated a partial response with a 31.7% decrease in lesion size by RECIST when treated with the combination of Kineret (anakinra), Ibrance (palbociclib), and Mekinist (trametinib) (PMID: 31782524).",
            "molecularProfile": {
                "id": 35186,
                "profileName": "CDKN2A R80* KRAS G12D"
            },
            "therapy": {
                "id": 9366,
                "therapyName": "Anakinra + Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17853,
                    "pubMedId": 31782524,
                    "title": "Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31782524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20624,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Kadcyla (ado-trastuzumab emtansine) treatment resulted in clinical benefit after one cycle of treatment, and stable disease with regression at lung metastasis after 3 cycles of treatment in a patient with colorectal adenocarcinoma harboring ERBB2 (HER2) amplification and KRAS G12D (PMID: 32023524).",
            "molecularProfile": {
                "id": 35271,
                "profileName": "ERBB2 amp KRAS G12D"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17974,
                    "pubMedId": 32023524,
                    "title": "Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32023524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20872,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing MET exon 14 skipping and KRAS G12D demonstrated decreased sensitivity to treatment with Xalkori (crizotinib) in culture and cell line xenograft models, which resulted in reduced tumor growth inhibition when compared to cells expressing only MET exon 14 skipping (PMID: 30352902).",
            "molecularProfile": {
                "id": 35374,
                "profileName": "KRAS G12D MET del exon14"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 18112,
                    "pubMedId": 30352902,
                    "title": "Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30352902"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20896,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing MET exon 14 skipping and KRAS G12D were sensitive to treatment with Mekinist (trametinib) in culture and demonstrated reduced tumor growth in cell line xenograft models (PMID: 30352902).",
            "molecularProfile": {
                "id": 35374,
                "profileName": "KRAS G12D MET del exon14"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18112,
                    "pubMedId": 30352902,
                    "title": "Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30352902"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20884,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing MET exon 14 skipping and KRAS G12D demonstrated decreased sensitivity to treatment with Cometriq (Cabometyx, cabozantinib) in culture compared to cells only expressing MET exon 14 skipping (PMID: 30352902).",
            "molecularProfile": {
                "id": 35374,
                "profileName": "KRAS G12D MET del exon14"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 18112,
                    "pubMedId": 30352902,
                    "title": "Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30352902"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20900,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Cometriq (Cabometyx, cabozantinib) and Mekinist (trametinib) resulted in a synergistic effect in cells expressing MET exon 14 skipping and KRAS G12D, demonstrating reduced cell growth in culture and decreased tumor volume in cell line xenograft models (PMID: 30352902).",
            "molecularProfile": {
                "id": 35374,
                "profileName": "KRAS G12D MET del exon14"
            },
            "therapy": {
                "id": 9500,
                "therapyName": "Cabozantinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18112,
                    "pubMedId": 30352902,
                    "title": "Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30352902"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 746,
            "profileName": "KRAS G12D",
            "profileTreatmentApproaches": [
                {
                    "id": 10548,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "KRAS G12D"
                },
                {
                    "id": 15267,
                    "name": "AZD4785",
                    "profileName": "KRAS G12D"
                },
                {
                    "id": 10545,
                    "name": "RAS Inhibitor (Pan)",
                    "profileName": "KRAS G12D"
                },
                {
                    "id": 10553,
                    "name": "PIK3CA inhibitor",
                    "profileName": "KRAS G12D"
                },
                {
                    "id": 10544,
                    "name": "MEK2 Inhibitor",
                    "profileName": "KRAS G12D"
                },
                {
                    "id": 10550,
                    "name": "MEK1 Inhibitor",
                    "profileName": "KRAS G12D"
                },
                {
                    "id": 10546,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "KRAS G12D"
                }
            ]
        },
        {
            "id": 5398,
            "profileName": "KRAS G12D PIK3CA G1049R PIK3CA amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5589,
            "profileName": "KRAS G12D PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 10717,
            "profileName": "KRAS G12D PIK3CA E453K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 10740,
            "profileName": "KRAS G12D PIK3CA G1049R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17216,
            "profileName": "KRAS G12D MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17217,
            "profileName": "KRAS G12D MET over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18158,
            "profileName": "KRAS G12D MYC over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18195,
            "profileName": "KRAS G12D TP53 R175H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18276,
            "profileName": "KRAS G12D YAP1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20862,
            "profileName": "KRAS G12D STK11 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20921,
            "profileName": "KRAS G12D STAT3 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20924,
            "profileName": "KRAS G12D STAT3 act mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20929,
            "profileName": "KRAS G12D STAT3 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21301,
            "profileName": "KRAS G12D PIK3CA Q546L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23661,
            "profileName": "EGFR L858R KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25295,
            "profileName": "IDH2 R172K KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25922,
            "profileName": "BRAF V600E KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26084,
            "profileName": "BRAF wild-type KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26340,
            "profileName": "EZH2 pos KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26364,
            "profileName": "KRAS G12D PTEN loss TP53 V216M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26365,
            "profileName": "KRAS G12D PTEN dec exp TP53 R306*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26369,
            "profileName": "KRAS G12D PIK3CA E545K PIK3CA H1047L TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26372,
            "profileName": "KRAS G12D PIK3CA H1047R TP53 R248W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26376,
            "profileName": "KRAS G12D PIK3CA H1047R TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26548,
            "profileName": "KRAS G12D PTEN pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26771,
            "profileName": "APC inact mut KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26772,
            "profileName": "APC inact mut KRAS G12D PTEN inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26839,
            "profileName": "KRAS G12D PIK3CA H1047R PTEN R130G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26840,
            "profileName": "CD274 pos KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27134,
            "profileName": "KRAS G12D THRB P447fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27260,
            "profileName": "IKBKE dec exp KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27819,
            "profileName": "KRAS G12D TP53 S127Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27864,
            "profileName": "KRAS G12D PIK3CA Q546R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27978,
            "profileName": "ATM del KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28318,
            "profileName": "KRAS G12D STK11 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28492,
            "profileName": "AKT1 over exp AKT2 over exp AKT3 over exp KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31087,
            "profileName": "BRAF G464E KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31380,
            "profileName": "KRAS G12D PTPN11 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31390,
            "profileName": "KRAS G12D PTPN11 E76A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32333,
            "profileName": "KRAS G12D MLH1 R389W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33509,
            "profileName": "CTRC - NTRK1 BRAF V600E KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33513,
            "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12A KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33515,
            "profileName": "LMNA - NTRK1 NTRK1 G595R KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33520,
            "profileName": "LMNA - NTRK1 KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33930,
            "profileName": "TPM3 - NTRK1 NTRK1 F589L NTRK1 G595R KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34503,
            "profileName": "KRAS G12D MET T1010I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35186,
            "profileName": "CDKN2A R80* KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35271,
            "profileName": "ERBB2 amp KRAS G12D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35374,
            "profileName": "KRAS G12D MET del exon14",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 157055,
            "transcript": "NM_033360",
            "gDna": "chr12:g.25245350C>T",
            "cDna": "c.35G>A",
            "protein": "p.G12D",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157058,
            "transcript": "XM_006719069",
            "gDna": "chr12:g.25245350C>T",
            "cDna": "c.35G>A",
            "protein": "p.G12D",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157057,
            "transcript": "XM_011520653",
            "gDna": "chr12:g.25245350C>T",
            "cDna": "c.35G>A",
            "protein": "p.G12D",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157056,
            "transcript": "XM_017019293",
            "gDna": "chr12:g.25245350C>T",
            "cDna": "c.35G>A",
            "protein": "p.G12D",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157054,
            "transcript": "NM_004985",
            "gDna": "chr12:g.25245350C>T",
            "cDna": "c.35G>A",
            "protein": "p.G12D",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}